{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:50:16Z","timestamp":1792673416114,"version":"4.5.0"},"reference-count":67,"publisher":"Portland Press Ltd.","issue":"11","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":414,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,15]]},"abstract":"<jats:p>Missense mutations in the LRRK2 (Leucine-rich repeat protein kinase-2) and VPS35 genes result in autosomal dominant Parkinson's disease. The VPS35 gene encodes for the cargo-binding component of the retromer complex, while LRRK2 modulates vesicular trafficking by phosphorylating a subgroup of Rab proteins. Pathogenic mutations in LRRK2 increase its kinase activity. It is not known how the only thus far described pathogenic VPS35 mutation, [p.D620N] exerts its effects. We reveal that the VPS35[D620N] knock-in mutation strikingly elevates LRRK2-mediated phosphorylation of Rab8A, Rab10, and Rab12 in mouse embryonic fibroblasts. The VPS35[D620N] mutation also increases Rab10 phosphorylation in mouse tissues (the lung, kidney, spleen, and brain). Furthermore, LRRK2-mediated Rab10 phosphorylation is increased in neutrophils as well as monocytes isolated from three Parkinson's patients with a heterozygous VPS35[D620N] mutation compared with healthy donors and idiopathic Parkinson's patients. LRRK2-mediated Rab10 phosphorylation is significantly suppressed by knock-out or knock-down of VPS35 in wild-type, LRRK2[R1441C], or VPS35[D620N] cells. Finally, VPS35[D620N] mutation promotes Rab10 phosphorylation more potently than LRRK2 pathogenic mutations. Available data suggest that Parkinson's patients with VPS35[D620N] develop the disease at a younger age than those with LRRK2 mutations. Our observations indicate that VPS35 controls LRRK2 activity and that the VPS35[D620N] mutation results in a gain of function, potentially causing PD through hyperactivation of the LRRK2 kinase. Our findings suggest that it may be possible to elaborate compounds that target the retromer complex to suppress LRRK2 activity. Moreover, patients with VPS35[D620N] associated Parkinson's might benefit from LRRK2 inhibitor treatment that have entered clinical trials in humans.<\/jats:p>","DOI":"10.1042\/bcj20180248","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T12:05:15Z","timestamp":1525867515000},"page":"1861-1883","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":221,"title":["The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human"],"prefix":"10.1042","volume":"475","author":[{"given":"Rafeeq","family":"Mir","sequence":"first","affiliation":[{"name":"MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tonelli","sequence":"additional","affiliation":[{"name":"MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Lis","sequence":"additional","affiliation":[{"name":"MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Macartney","sequence":"additional","affiliation":[{"name":"MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole K.","family":"Polinski","sequence":"additional","affiliation":[{"name":"The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station, PO Box 4777, New York, NY 10163, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terina N.","family":"Martinez","sequence":"additional","affiliation":[{"name":"The Michael J. Fox Foundation for Parkinson's Research, Grand Central Station, PO Box 4777, New York, NY 10163, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yun","family":"Chou","sequence":"additional","affiliation":[{"name":"Abcam, 863 Mitten Rd, Burlingame, CA 94010, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.M.","family":"Howden","sequence":"additional","affiliation":[{"name":"Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hotzy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Milenkovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Br\u00fccke","sequence":"additional","affiliation":[{"name":"Verein zur F\u00f6rderung der wissenschaftlichen Forschung im, Wilhelminenspital (FWFW), Montleartstrasse 37, 1160 Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zimprich","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sammler","sequence":"additional","affiliation":[{"name":"MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K."},{"name":"Department of Neurology, School of Medicine, Dundee, Ninewells Hospital, Ninewells Drive, Dundee DD1 9SY, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario R.","family":"Alessi","sequence":"additional","affiliation":[{"name":"MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"2021112216524975600_BCJ-2018-0248C1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","article-title":"Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030","volume":"68","author":"Dorsey","year":"2007","journal-title":"Neurology"},{"issue":"suppl 1","key":"2021112216524975600_BCJ-2018-0248C2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jnc.13593","article-title":"Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance","volume":"139","author":"Hernandez","year":"2016","journal-title":"J. Neurochem."},{"key":"2021112216524975600_BCJ-2018-0248C3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/B978-0-444-63233-3.00014-2","article-title":"Genetics of Parkinson disease","volume":"147","author":"Domingo","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"2021112216524975600_BCJ-2018-0248C4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"},{"key":"2021112216524975600_BCJ-2018-0248C5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Pais\u00e1n-Ru\u0131\u00b4z","year":"2004","journal-title":"Neuron"},{"key":"2021112216524975600_BCJ-2018-0248C6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1126\/science.aar5683","article-title":"LRRK2 kinase in Parkinson's disease","volume":"360","author":"Alessi","year":"2018","journal-title":"Science"},{"key":"2021112216524975600_BCJ-2018-0248C7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.parkreldis.2010.11.008","article-title":"Genetic characteristics of Leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease","volume":"17","author":"Bardien","year":"2011","journal-title":"Parkinsonism. Relat. Disord."},{"key":"2021112216524975600_BCJ-2018-0248C8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1326-9-47","article-title":"The role of the LRRK2 gene in Parkinsonism","volume":"9","author":"Li","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"2021112216524975600_BCJ-2018-0248C9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nrn2935","article-title":"The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease","volume":"11","author":"Cookson","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"2021112216524975600_BCJ-2018-0248C10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.201798099","article-title":"Rab29 activation of the Parkinson's disease-associated LRRK2 kinase","volume":"37","author":"Purlyte","year":"2018","journal-title":"EMBO J."},{"key":"2021112216524975600_BCJ-2018-0248C11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/hmg\/ddx410","article-title":"LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network","volume":"27","author":"Liu","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C12","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.bbrc.2017.12.024","article-title":"Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology","volume":"495","author":"Fujimoto","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112216524975600_BCJ-2018-0248C13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.7554\/eLife.12813","article-title":"Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases","volume":"5","author":"Steger","year":"2016","journal-title":"eLife"},{"key":"2021112216524975600_BCJ-2018-0248C14","doi-asserted-by":"publisher","first-page":"e80705","DOI":"10.7554\/eLife.31012","article-title":"Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis","volume":"6","author":"Steger","year":"2017","journal-title":"eLife"},{"key":"2021112216524975600_BCJ-2018-0248C15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1152\/physrev.00059.2009","article-title":"Role of Rab GTPases in membrane traffic and cell physiology","volume":"91","author":"Hutagalung","year":"2011","journal-title":"Physiol. Rev."},{"key":"2021112216524975600_BCJ-2018-0248C16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ceb.2013.04.002","article-title":"Rab GTPase regulation of membrane identity","volume":"25","author":"Pfeffer","year":"2013","journal-title":"Curr. Opin. Cell Biol."},{"key":"2021112216524975600_BCJ-2018-0248C17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13024-018-0240-1","article-title":"Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration","volume":"13","author":"Jeong","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"2021112216524975600_BCJ-2018-0248C18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1091\/mbc.e12-08-0598","article-title":"The Rilp-like proteins Rilpl1 and Rilpl2 regulate ciliary membrane content","volume":"24","author":"Schaub","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"2021112216524975600_BCJ-2018-0248C19","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1042\/BCJ20160557","article-title":"Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors","volume":"473","author":"Ito","year":"2016","journal-title":"Biochem. J."},{"key":"2021112216524975600_BCJ-2018-0248C20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BCJ20170802","article-title":"Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase","volume":"475","author":"Lis","year":"2018","journal-title":"Biochem. J."},{"key":"2021112216524975600_BCJ-2018-0248C21","doi-asserted-by":"publisher","first-page":"R471","DOI":"10.1016\/j.cub.2018.02.010","article-title":"Rab GTPases and membrane trafficking in neurodegeneration","volume":"28","author":"Kiral","year":"2018","journal-title":"Curr. Biol."},{"key":"2021112216524975600_BCJ-2018-0248C22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/mds.27270","article-title":"The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease","volume":"33","author":"Gao","year":"2018","journal-title":"Mov. Disord."},{"key":"2021112216524975600_BCJ-2018-0248C23","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.15252\/embj.201591593","article-title":"Phosphoproteomic screening identifies Rab GTPases as novel downstream targets of PINK1","volume":"34","author":"Lai","year":"2015","journal-title":"EMBO J."},{"key":"2021112216524975600_BCJ-2018-0248C24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1126\/science.1129462","article-title":"\u03b1-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models","volume":"313","author":"Cooper","year":"2006","journal-title":"Science"},{"key":"2021112216524975600_BCJ-2018-0248C25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13024-016-0140-1","article-title":"LRRK2 at the interface of autophagosomes, endosomes and lysosomes","volume":"11","author":"Roosen","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"2021112216524975600_BCJ-2018-0248C26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/mds.25430","article-title":"The VPS35 gene and Parkinson's disease","volume":"28","author":"Deng","year":"2013","journal-title":"Mov. Disord."},{"key":"2021112216524975600_BCJ-2018-0248C27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","article-title":"A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease","volume":"89","author":"Zimprich","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","article-title":"VPS35 mutations in Parkinson disease","volume":"89","author":"Vilari\u00f1o-G\u00fcell","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3233\/JPD-161020","article-title":"VPS35, the retromer complex and Parkinson's disease","volume":"7","author":"Williams","year":"2017","journal-title":"J. Parkinsons's Dis."},{"key":"2021112216524975600_BCJ-2018-0248C30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/jmedgenet-2012-101155","article-title":"A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants","volume":"49","author":"Sharma","year":"2012","journal-title":"J. Med. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nature06216","article-title":"Functional architecture of the retromer cargo-recognition complex","volume":"449","author":"Hierro","year":"2007","journal-title":"Nature"},{"key":"2021112216524975600_BCJ-2018-0248C32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.neuron.2012.11.033","article-title":"RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk","volume":"77","author":"MacLeod","year":"2013","journal-title":"Neuron"},{"key":"2021112216524975600_BCJ-2018-0248C33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1750-1326-9-23","article-title":"Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2)","volume":"9","author":"Linhart","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"2021112216524975600_BCJ-2018-0248C34","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/hmg\/ddx179","article-title":"Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in drosophila","volume":"26","author":"Inoshita","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021112216524975600_BCJ-2018-0248C36","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-Pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J. Med. Chem."},{"key":"2021112216524975600_BCJ-2018-0248C37","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.1016\/j.bmcl.2012.06.104","article-title":"GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor","volume":"22","author":"Reith","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2021112216524975600_BCJ-2018-0248C38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/jm5014055","article-title":"Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7 H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor","volume":"58","author":"Henderson","year":"2015","journal-title":"J. Med. Chem."},{"key":"2021112216524975600_BCJ-2018-0248C39","doi-asserted-by":"publisher","first-page":"9348","DOI":"10.1073\/pnas.92.20.9348","article-title":"Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas","volume":"92","author":"Spieker-Polet","year":"1995","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216524975600_BCJ-2018-0248C40","first-page":"429","article-title":"Fusion partner for production of monoclonal rabbit antibodies","volume":"7","author":"Pytela","year":"2008","journal-title":"United States patent."},{"key":"2021112216524975600_BCJ-2018-0248C41","doi-asserted-by":"publisher","first-page":"e39132","DOI":"10.1371\/journal.pone.0039132","article-title":"The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during toll-like receptor signaling","volume":"7","author":"Dzamko","year":"2012","journal-title":"PLoS ONE"},{"key":"2021112216524975600_BCJ-2018-0248C42","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1128\/MCB.22.8.2871-2881.2002","article-title":"MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts","volume":"22","author":"Wiggin","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"2021112216524975600_BCJ-2018-0248C43","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","article-title":"Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein","volume":"64","author":"Lin","year":"2009","journal-title":"Neuron"},{"key":"2021112216524975600_BCJ-2018-0248C44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1042\/BCJ20170803","article-title":"Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils","volume":"475","author":"Fan","year":"2018","journal-title":"Biochem. J."},{"key":"2021112216524975600_BCJ-2018-0248C45","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1093\/hmg\/ddw279","article-title":"Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice","volume":"25","author":"Ishizu","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C46","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/hmg\/ddu582","article-title":"Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N","volume":"24","author":"Munsie","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C47","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1093\/hmg\/ddu178","article-title":"Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration","volume":"23","author":"Tsika","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C48","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1038\/ncomms4828","article-title":"Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy","volume":"5","author":"Zavodszky","year":"2014","journal-title":"Nat. Commun."},{"key":"2021112216524975600_BCJ-2018-0248C49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1042\/BJ20100784","article-title":"Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910\/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization","volume":"430","author":"Dzamko","year":"2010","journal-title":"Biochem. J."},{"key":"2021112216524975600_BCJ-2018-0248C50","doi-asserted-by":"publisher","first-page":"164ra161","DOI":"10.1126\/scitranslmed.3004485","article-title":"Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations","volume":"4","author":"Sheng","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"2021112216524975600_BCJ-2018-0248C51","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ni.3693","article-title":"Social network architecture of human immune cells unveiled by quantitative proteomics","volume":"18","author":"Rieckmann","year":"2017","journal-title":"Nat. Immunol."},{"key":"2021112216524975600_BCJ-2018-0248C52","doi-asserted-by":"publisher","first-page":"235","DOI":"10.15252\/embj.201797128","article-title":"Control of RAB7 activity and localization through the retromer-TBC1D5 complex enables RAB7-dependent mitophagy","volume":"37","author":"Jimenez-Orgaz","year":"2018","journal-title":"EMBO J."},{"key":"2021112216524975600_BCJ-2018-0248C53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","article-title":"The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease","volume":"85","author":"Pickrell","year":"2015","journal-title":"Neuron"},{"key":"2021112216524975600_BCJ-2018-0248C54","doi-asserted-by":"publisher","first-page":"120080","DOI":"10.1098\/rsob.120080","article-title":"PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65","volume":"2","author":"Kondapalli","year":"2012","journal-title":"Open Biol."},{"key":"2021112216524975600_BCJ-2018-0248C55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1042\/BJ20140334","article-title":"Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65","volume":"460","author":"Kazlauskaite","year":"2014","journal-title":"Biochem. J."},{"key":"2021112216524975600_BCJ-2018-0248C56","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1073\/pnas.1318306111","article-title":"Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease","volume":"111","author":"Beilina","year":"2014","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216524975600_BCJ-2018-0248C57","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/jhg.2015.34","article-title":"Fine mapping and resequencing of the PARK16 locus in Parkinson's disease","volume":"60","author":"Pihlstr\u00f8m","year":"2015","journal-title":"J. Hum. Genet."},{"key":"2021112216524975600_BCJ-2018-0248C58","doi-asserted-by":"publisher","first-page":"29945","DOI":"10.1038\/srep29945","article-title":"LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts","volume":"6","author":"Kuwahara","year":"2016","journal-title":"Sci. Rep."},{"key":"2021112216524975600_BCJ-2018-0248C59","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/mds.26651","article-title":"Launching the movement disorders society genetic mutation database (MDSGene)","volume":"31","author":"Lill","year":"2016","journal-title":"Mov. Disord."},{"key":"2021112216524975600_BCJ-2018-0248C60","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/mds.27059","article-title":"Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry","volume":"32","author":"Lee","year":"2017","journal-title":"Mov. Disord."},{"key":"2021112216524975600_BCJ-2018-0248C61","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/mds.21525","article-title":"High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal","volume":"22","author":"Ferreira","year":"2007","journal-title":"Mov. Disord."},{"key":"2021112216524975600_BCJ-2018-0248C62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neulet.2010.08.029","article-title":"Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease","volume":"485","author":"Yescas","year":"2010","journal-title":"Neurosci. Lett."},{"key":"2021112216524975600_BCJ-2018-0248C63","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10048-008-0162-0","article-title":"LRRK2 g2019s and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity","volume":"10","author":"Gorostidi","year":"2009","journal-title":"Neurogenetics"},{"key":"2021112216524975600_BCJ-2018-0248C64","doi-asserted-by":"publisher","first-page":"M110.001172","DOI":"10.1074\/mcp.M110.001172","article-title":"A QUICK screen for Lrrk2 interaction partners \u2014 leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics","volume":"10","author":"Meixner","year":"2011","journal-title":"Mol. Cell. Proteomics"},{"key":"2021112216524975600_BCJ-2018-0248C65","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.cub.2014.06.024","article-title":"Retromer binding to FAM21 and the WASH complex is perturbed by the Parkinson disease-linked VPS35(D620N) mutation","volume":"24","author":"McGough","year":"2014","journal-title":"Curr. Biol."},{"key":"2021112216524975600_BCJ-2018-0248C66","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.expneurol.2017.07.019","article-title":"Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease","volume":"298","author":"West","year":"2017","journal-title":"Exp. Neurol."},{"key":"2021112216524975600_BCJ-2018-0248C67","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-3-319-49969-7_13","article-title":"Small-molecule inhibitors of LRRK2","volume":"14","author":"Hatcher","year":"2017","journal-title":"Adv. Neurobiol."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/475\/11\/1861\/691623\/bcj-2018-0248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/475\/11\/1861\/691623\/bcj-2018-0248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T18:37:13Z","timestamp":1637606233000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/475\/11\/1861\/49757\/The-Parkinson-s-disease-VPS35-D620N-mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,6,15]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20180248","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733211966.793580403","asserted-by":"object"}]},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]}}}